The aim of the CO-FLOW study is to follow the health care paths of all COVID-19 patients who survived hospitalization in the Rotterdam-Rijnmond region over a 2 years-period and to systematically study physical, cognitive and psychological health outcomes over time.

The data are sensitive since they involve personal information of patients. There are restrictions on use by commercial parties and on sharing openly, based on (inter)national laws and regulations and written informed consent. Therefore these data (and additional clinical data) are only available upon signing a Data Transfer Agreement (see Terms of Access).